RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.